STAMFORD, Conn.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq:DCTH), a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents, today announced that President and Chief Executive Officer, Richard L. Taney, has released a letter to shareholders in which he reviews the Company’s strategic developments, including the recent five year extension to the Cooperative Research and Development Agreement (“CRADA”) with the National Cancer Institute. The following letter accompanied the recently released proxy statement:
